SCHEMBL4293172

SCHEMBL4293172

CCn1c(-c2nonc2N)nc2c(Cl)ncc(OCCCN3CCCC3)c21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 15/20 0.56
RPS6KA1 Q15418 13/20 0.56
RPS6KA5 O75582 8/20 0.56
ROCK1 Q13464 14/20 0.56
SLC2A1 P11166 1/20 0.53
AKT2 P31751 5/20 0.52
AKT3 Q9Y243 2/20 0.52
CIT O14578 1/20 0.44
DCLK1 O15075 1/20 0.44
DAPK3 O43293 1/20 0.44
NUAK1 O60285 1/20 0.44
PIP5K1C O60331 1/20 0.44
ROCK2 O75116 1/20 0.44
ULK1 O75385 1/20 0.44
RPS6KA4 O75676 1/20 0.44
PRKD3 O94806 1/20 0.44
SMC2 O95347 1/20 0.44
LATS1 O95835 1/20 0.44
PAK4 O96013 1/20 0.44
CHEK2 O96017 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4290706 0.99 AKT1 (0.56) AKT1RPS6KA1RPS6KA5ROCK1SLC2A1
SCHEMBL4301462 0.98 AKT1 (0.56) AKT1RPS6KA1RPS6KA5ROCK1SLC2A1
SCHEMBL21350454 0.87 AKT1 (0.73) AKT1RPS6KA1RPS6KA5ROCK1SLC2A1
SCHEMBL13702620 0.86 AKT1 (0.60) AKT1RPS6KA1RPS6KA5ROCK1AKT2
SCHEMBL4295261 0.86 AKT1 (0.61) AKT1RPS6KA1RPS6KA5ROCK1SLC2A1
SCHEMBL13702607 0.85 AKT1 (0.59) AKT1RPS6KA1RPS6KA5ROCK1AKT2
SCHEMBL4295597 0.83 AKT1 (0.79) AKT1RPS6KA1RPS6KA5ROCK1AKT2
SCHEMBL4299419 0.82 AKT1 (0.56) AKT1RPS6KA1RPS6KA5ROCK1SLC2A1
SCHEMBL4294982 0.82 AKT1 (0.78) AKT1RPS6KA1RPS6KA5ROCK1AKT2
Hydrochloric Acid SCHEMBL4292124 0.81 AKT1 (0.77) AKT1RPS6KA1RPS6KA5ROCK1AKT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227616-A1 INHIBITORS OF AKT ACTIVITY SMITHKLINE BEECHAM CORPORATION, A CORPORATION 2009-09-10 US disclosed
EP-1948185-A2 INHIBITORS OF AKT ACTIVITY SmithKline Beecham Corporation (US) 2008-07-30 EP disclosed
WO-2007058852-A2 INHIBITORS OF AKT ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2007-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227616-A1 INHIBITORS OF AKT ACTIVITY PI4KB, PIK3CA, AKT2 AKT1 5/4885RPS6KA1 127/4885RPS6KA5 156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.